HRP20181315T1 - Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina - Google Patents

Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina

Info

Publication number
HRP20181315T1
HRP20181315T1 HRP20181315TT HRP20181315T HRP20181315T1 HR P20181315 T1 HRP20181315 T1 HR P20181315T1 HR P20181315T T HRP20181315T T HR P20181315TT HR P20181315 T HRP20181315 T HR P20181315T HR P20181315 T1 HRP20181315 T1 HR P20181315T1
Authority
HR
Croatia
Prior art keywords
proteins
extraction
protein expression
signal sequences
new signal
Prior art date
Application number
HRP20181315TT
Other languages
English (en)
Croatian (hr)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of HRP20181315T1 publication Critical patent/HRP20181315T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20181315TT 2010-11-22 2011-11-22 Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina HRP20181315T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
EP11843849.8A EP2643468B1 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (1)

Publication Number Publication Date
HRP20181315T1 true HRP20181315T1 (hr) 2018-10-19

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181315TT HRP20181315T1 (hr) 2010-11-22 2011-11-22 Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina

Country Status (19)

Country Link
US (1) US9279007B2 (OSRAM)
EP (2) EP3461905B1 (OSRAM)
JP (1) JP2014503198A (OSRAM)
KR (2) KR101984318B1 (OSRAM)
CN (1) CN103328649B (OSRAM)
BR (1) BR112013012671B1 (OSRAM)
CA (1) CA2818689C (OSRAM)
CY (1) CY1121049T1 (OSRAM)
DK (2) DK3461905T3 (OSRAM)
ES (2) ES2687415T3 (OSRAM)
HR (1) HRP20181315T1 (OSRAM)
HU (1) HUE039070T2 (OSRAM)
LT (1) LT2643468T (OSRAM)
PL (1) PL2643468T3 (OSRAM)
PT (1) PT2643468T (OSRAM)
RS (1) RS57601B1 (OSRAM)
SI (1) SI2643468T1 (OSRAM)
SM (1) SMT201800466T1 (OSRAM)
WO (1) WO2012071422A2 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192243T1 (hr) 2014-07-03 2020-03-06 F. Hoffmann - La Roche Ag Polipeptidni ekspresijski sustavi
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN110809583A (zh) 2017-06-07 2020-02-18 瑞泽恩制药公司 用于内化酶的组合物和方法
TW201927825A (zh) * 2017-11-30 2019-07-16 美商阿米庫斯醫療股份有限公司 Cdkl5 表現變體和cdkl5 融合蛋白
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
BR112020021962A2 (pt) * 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
MX2020012350A (es) 2018-05-17 2021-01-29 Regeneron Pharma Anticuerpos anti-cd63, conjugados y usos de estos.
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3863663A2 (en) 2018-10-10 2021-08-18 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
KR20210105382A (ko) * 2018-12-19 2021-08-26 베르사멥 아게 단백질을 코딩하는 rna
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
BR112021021720A2 (pt) * 2019-04-30 2021-12-28 Univ Pennsylvania Composições úteis para tratamento de doença de pompe
EP3983538A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
CA3200192A1 (en) 2020-12-01 2022-06-09 Justin PERCIVAL Compositions and uses thereof for treatment of angelman syndrome
US20250034533A1 (en) 2021-11-12 2025-01-30 Amicus Therapeutics, Inc. Compositions And Methods For Treating Mucopolysaccharidosis IIIA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352286C (en) * 1998-11-24 2011-07-12 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kd heat shock protein
US7279564B2 (en) * 2003-11-06 2007-10-09 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Also Published As

Publication number Publication date
BR112013012671A2 (pt) 2016-10-11
KR101984318B1 (ko) 2019-05-31
WO2012071422A3 (en) 2012-08-02
CA2818689C (en) 2021-09-21
PT2643468T (pt) 2018-10-11
BR112013012671B1 (pt) 2022-03-03
HUE039070T2 (hu) 2018-12-28
CY1121049T1 (el) 2019-12-11
DK2643468T3 (en) 2018-09-24
EP2643468A2 (en) 2013-10-02
EP2643468B1 (en) 2018-07-04
ES2829199T3 (es) 2021-05-31
ES2687415T3 (es) 2018-10-25
PL2643468T3 (pl) 2018-11-30
LT2643468T (lt) 2018-09-10
KR20190060888A (ko) 2019-06-03
KR20130121878A (ko) 2013-11-06
JP2014503198A (ja) 2014-02-13
EP3461905A1 (en) 2019-04-03
US20140045216A1 (en) 2014-02-13
EP2643468A4 (en) 2014-12-24
EP3461905B1 (en) 2020-08-05
CN103328649A (zh) 2013-09-25
DK3461905T3 (da) 2020-11-02
WO2012071422A2 (en) 2012-05-31
CN103328649B (zh) 2016-06-22
CA2818689A1 (en) 2012-05-31
US9279007B2 (en) 2016-03-08
SMT201800466T1 (it) 2018-11-09
RS57601B1 (sr) 2018-11-30
SI2643468T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
HRP20181315T1 (hr) Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
EP2553102A4 (en) HIGH PERFORMANCE EXPRESSION OF RECOMBINANT TOXIN PROTEINS
EP2547771A4 (en) PREPARATION OF PROTEINS AND POLYPEPTIDES
EP2408921A4 (en) MODIFICATION OF CXCR4 USING MODIFIED ZINC FINGER PROTEINS
EP2426200A4 (en) PROTEIN ELECTRON MEDIATOR
HRP20181154T1 (hr) Konjugati antitijela i lijeka (adc) koji se vežu za 191p4d12 proteine
BRPI1015350A2 (pt) anticorpos de anti-ceacam1 e métodos de usar os mesmos
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
BR112013014457A2 (pt) método com base em mgmt para obter alta produção de expressão de proteína recombinante
EA201171494A1 (ru) Миметики белка smac
SMT201600033B (it) COMPOSIZIONI E METODI RELATIVI A VARIANTI DELLA PROTEINA A (SpA)
SMT201600314B (it) Coniugati di proteina di coagulazione di sangue
EP2566346A4 (en) PREPARATION OF SOLUBLE PROTEIN SOLUTIONS FROM PULSES
HRP20170983T1 (hr) Pripravci s visokom koncentracijom antitijela
PL3756657T3 (pl) Preparaty peptydu n-końcowego aneksyny a1 i sposoby
DK3578659T3 (da) Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression
EP2563435A4 (en) ADMINISTRATION OF ULTRA PURE NITROGEN MONOXIDE (NO)
BR112013019677A2 (pt) composições nutricionais altamente protéicas e métodos de fazer e usar as mesmas
EP2566333A4 (en) IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
PT2753352T (pt) Péptido isolado das proteínas da toxina a e da toxina b de c. difficile e suas utilizações
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
DK2598516T3 (da) Fremgangsmåde til proteinoprensning
IL232645B (en) Recombinant proteins and their therapeutic uses
SMT201600147B (it) Metodi per migliorare l'espressione di proteine ricombinanti
EA201792608A2 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид